JP2010513901A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513901A5
JP2010513901A5 JP2009542216A JP2009542216A JP2010513901A5 JP 2010513901 A5 JP2010513901 A5 JP 2010513901A5 JP 2009542216 A JP2009542216 A JP 2009542216A JP 2009542216 A JP2009542216 A JP 2009542216A JP 2010513901 A5 JP2010513901 A5 JP 2010513901A5
Authority
JP
Japan
Prior art keywords
peptide
seq
fragment
hox
homeodomain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513901A (ja
JP5683108B2 (ja
Filing date
Publication date
Priority claimed from GBGB0625321.5A external-priority patent/GB0625321D0/en
Application filed filed Critical
Publication of JP2010513901A publication Critical patent/JP2010513901A/ja
Publication of JP2010513901A5 publication Critical patent/JP2010513901A5/ja
Application granted granted Critical
Publication of JP5683108B2 publication Critical patent/JP5683108B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542216A 2006-12-19 2007-12-19 癌バイオマーカー Expired - Fee Related JP5683108B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0625321.5 2006-12-19
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GB0719792.4 2007-10-10
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (3)

Publication Number Publication Date
JP2010513901A JP2010513901A (ja) 2010-04-30
JP2010513901A5 true JP2010513901A5 (https=) 2011-01-27
JP5683108B2 JP5683108B2 (ja) 2015-03-11

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542216A Expired - Fee Related JP5683108B2 (ja) 2006-12-19 2007-12-19 癌バイオマーカー

Country Status (19)

Country Link
US (1) US8460882B2 (https=)
EP (1) EP2115472B1 (https=)
JP (1) JP5683108B2 (https=)
CN (1) CN101675341B (https=)
AU (1) AU2007335999B2 (https=)
BR (1) BRPI0720371B8 (https=)
CA (1) CA2671939C (https=)
CY (1) CY1115178T1 (https=)
DK (1) DK2115472T3 (https=)
ES (1) ES2445185T3 (https=)
GB (2) GB0625321D0 (https=)
IL (1) IL199241A (https=)
MX (1) MX2009006378A (https=)
NZ (1) NZ577548A (https=)
PL (1) PL2115472T3 (https=)
PT (1) PT2115472E (https=)
RU (1) RU2460075C2 (https=)
SI (1) SI2115472T1 (https=)
WO (1) WO2008075056A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
RU2012100903A (ru) * 2009-07-13 2013-08-20 Зе Юниверсити Оф Саррей Терапевтические пептиды, полипептиды и последовательности нуклеиновых кислот
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2013037118A1 (zh) * 2011-09-16 2013-03-21 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
MX2014006662A (es) * 2011-12-05 2015-04-16 Phigenix Inc Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
WO2014025961A1 (en) * 2012-08-10 2014-02-13 Analiza, Inc. Methods and devices for analyzing species to determine diseases
AU2013388864B2 (en) * 2013-05-09 2017-06-08 The Procter & Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) * 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
WO2016193110A1 (en) * 2015-05-29 2016-12-08 Koninklijke Philips N.V. Methods of prostate cancer prognosis
EP3352777B1 (en) * 2015-09-23 2021-09-15 Centre National De La Recherche Scientifique Engrailed for use in the treatment of dna-damage in a patient suffering from parkinson disease
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
JP6855579B2 (ja) * 2016-12-28 2021-04-07 中国科学院広州生物医薬与健康研究院Guangzhou Institutes Of Biomedicine And Health,Chinese Academy Of Sciences T細胞を得る方法及び使用
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777254B1 (ko) 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒
WO2023076036A1 (en) 2021-10-28 2023-05-04 Analiza, Inc. Partitioning systems and methods for determining multiple types of cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295303A1 (en) * 1997-06-27 1999-01-07 Human Genome Sciences Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
CA2347081A1 (en) * 1998-10-19 2000-04-27 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US20040029208A1 (en) 2000-05-30 2004-02-12 Ravn Helle Weber Assay method and kit for testing biological material for exposure to stress using biomarkers
WO2002000926A2 (en) * 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
WO2002022884A2 (en) * 2000-09-12 2002-03-21 Transgenetics Incorporated Microarrayed organization of transcription factor target genes
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
AU2002249834B2 (en) 2000-12-24 2008-05-22 Iser Lubocki A method for detecting biomarkers
US20020137086A1 (en) * 2001-03-01 2002-09-26 Alexander Olek Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
CA2593546A1 (en) * 2004-12-02 2006-07-06 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US9416422B2 (en) * 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease

Similar Documents

Publication Publication Date Title
JP2010513901A5 (https=)
RU2009127774A (ru) Биомаркеры рака
Hudler et al. Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics
US10345309B2 (en) Biomarkers for gastric cancer and uses thereof
EP2796878A1 (en) New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
JP4916441B2 (ja) 結腸直腸腺腫及び/又は癌腫に対するバイオマーカーとしてのトランスサイレチンの使用;検出方法及び試験システム
US20220268776A1 (en) Biomarker panel for diagnosing pancreatic cancer and use thereof
JP6774925B2 (ja) 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療のための方法並びにそのキット
KR101520615B1 (ko) 간암 진단용 바이오 마커
TWI408370B (zh) 胰臟癌之血清生物檢測標誌及其應用
CN104272112B (zh) 用于帮助诊断中风的基于生物标记的方法和生物芯片
JP4516124B2 (ja) 肝線維症の診断方法
EP2569451A1 (en) Methods and devices for diagnosing alzheimers disease
US20130210667A1 (en) Biomarkers for Predicting Kidney and Glomerular Pathologies
CN108841954A (zh) 生物标志物在卵巢癌评估中的应用
JP2016530545A (ja) 卵巣がんに関するバイオマーカー
AU2014247083B2 (en) Methods and arrays for use in biomarker detection for prostate cancer
JP2012526543A5 (https=)
US20140248637A1 (en) Composition for diagnosis of lung cancer and diagnosis kit of lung cancer
KR20230113742A (ko) 난소암의 검출 및 치료를 위한 방법
EP3827098A1 (en) Method of diagnosing asthma subtypes
WO2023230584A1 (en) Methods and systems for risk stratification and management of bladder cancer
CN120442791B (zh) 非功能性胰腺神经内分泌肿瘤预后标志物及其应用
KR20210015259A (ko) 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법